Study Comparing Four New Formulations for Premarin in Healthy Postmenopausal Women

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to determine bioequivalence and bioavailability of four different Premarin/MPA test formulations versus the current formulation for Prempro.

• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Estrogens, Conjugated (USP); Medroxyprogesterone; Medroxyprogesterone Acetate

Criteria

Inclusion Criteria:

1. Healthy postmenopausal women aged 35 to 70 years

2. Nonsmoker or smoker of less than 10 cigarettes per day

Exclusion Criteria:

1. History or presence of clotting disorders

2. History or presence of cancer

3. Presence of HIV, hepatitis B or hepatitis C

4. History of drug or alcohol abuse